Insights into your baby’s health as early as nine weeks into your pregnancy

The pioneering NIPT-safe, accurate, and ordered more than 1 million times to date
A noninvasive blood test
With a blood draw from you as early as nine weeks into your pregnancy, the MaterniT® 21 PLUS test can screen for certain chromosomal abnormalities that could affect your baby’s health and development, providing you with more information earlier in your pregnancy.

What it screens for—and why

Like most noninvasive prenatal tests (NIPT), MaterniT 21 PLUS screens for certain chromosomal abnormalities called trisomies, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).

But it digs deeper, screening for certain sex chromosome aneuploidies (SCAs, abnormal numbers of X or Y chromosomes) and select microdeletions (missing parts of chromosomes).

While rare, these chromosomal abnormalities can have profound consequences in the life and health of your child. Detecting this information early can help your doctor recommend specialized care for you and your baby, before and after delivery.

The MaterniT 21 PLUS test detects the following chromosomal abnormalities:

<table>
<thead>
<tr>
<th>TRISOMIES</th>
<th>SCAS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy 21 (Down syndrome)</td>
<td>45,X (Turner syndrome)</td>
</tr>
<tr>
<td>Trisomy 18 (Edwards syndrome)</td>
<td>47,XXY (Klinefelter syndrome)</td>
</tr>
<tr>
<td>Trisomy 13 (Patau syndrome)</td>
<td>47,XXX (Triple X syndrome)</td>
</tr>
<tr>
<td>Trisomy 16*</td>
<td>47,XY (XYY syndrome)</td>
</tr>
<tr>
<td>Trisomy 22*</td>
<td></td>
</tr>
</tbody>
</table>
Why “noninvasive?”

There are many ways to get this information, including methods such as serum screens and diagnostic procedures such as amniocentesis.

As a noninvasive prenatal test, MaterniT 21 PLUS is different from both. It has higher detection rates than serum screening¹ (determined to be 97.9% positive predictive value for trisomy 21 in a high-risk cohort²), and requires only a blood draw from the mother; amniocentesis requires withdrawing fluid from around the developing baby.

Most women who get the MaterniT 21 PLUS will screen negative for chromosomal abnormalities and may not require further testing.

However, any patient with a positive test result may be offered genetic counseling and/or diagnostic testing for confirmation of test results.

Clear results, delivered quickly

The test delivers clear positive or negative results for well known chromosomal abnormalities, such as trisomy 21 (Down syndrome), typically returned in about five days from the receipt of your blood draw at our lab in California.

Also, if you’re carrying twins, MaterniT 21 PLUS can detect common chromosomal abnormalities in multiple gestation pregnancies.
### Understand your cost options
Visit our website for your cost estimate and personalized payment options and the opportunity to learn about our Moms Helping Moms of Tomorrow initiative. www.integratedgenetics.com/transparency

### Convenient blood draws
Getting your blood drawn is easier than ever. As a LabCorp company, we have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit www.LabCorp.com to find your nearest location.

### Genetic counseling
Patients with a positive test result may be offered counseling, and Sequenom and Integrated Genetics offer the largest national commercial network of genetic counselors to help inform and support patients.

### Every Mom Pledge
We believe every mom should have access to the best possible care. That's why we work directly with you to make sure our testing services are accessible and out-of-pocket costs are transparent.
Sequenom Laboratories
3595 John Hopkins Court
San Diego, CA 92121

Sequenom Center for Molecular Medicine, LLC d/b/a Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc., is a CAP-accredited and Clinical Laboratory Improvement Amendment (CLIA)-certified molecular diagnostics laboratory dedicated to improving patient outcomes by offering revolutionary laboratory-developed tests for a variety of prenatal conditions. Sequenom, Inc. is a wholly owned subsidiary of Laboratory Corporation of America Holdings. Sequenom®, Sequenom Laboratories™, and MaterniT® are trademarks of Sequenom, Inc. This brochure is provided by Integrated Genetics as an educational service for healthcare providers and their patients.

Note: This material is provided for general information purposes only. It is not intended as a substitute for medical advice and/or consultation with a physician or technical expert.

REFERENCES